Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Chardan Capital's Geulah Livshits raised their price target on Palvella Therapeutics (NASDAQ: PVLA) by 14.3% from $210 to $240 on 2026/04/01. The analyst maintained their Strong Buy rating on the stock.

Palvella Therapeutics reported its FY 2025 earnings.

On the earnings call, management focused on the company's expanding pipeline of topical therapies, Livshits told readers.

The analyst said the company's cash position should be sufficient to see it through the initial approval and launch in microcystic lymphatic malformations.

Earnings Report

For FY 2025, Palvella Therapeutics reported:

• Loss per share of $3.71, compared to FY 2024’s loss of $7.83.

Management did not provide EPS and revenue guidance in its press release.

Founder & CEO Wes Kaupinen commented: “2025 was a landmark year for Palvella, and we carried that momentum into 2026 with positive Phase 3 SELVA results in microcystic lymphatic malformations, marking a major milestone for the company and putting us on a path toward our first potential FDA approval in 1H 2027.

“Following SELVA results, we significantly strengthened our balance sheet through an oversubscribed $230.0 million financing, enabling us to accelerate U.S. launch readiness and continue advancing novel topical product candidates from our QTORIN™ platform. 

“Supported by Breakthrough Therapy, Fast Track, and Orphan designations, we are now focused on advancing QTORIN™ rapamycin toward an NDA submission while preparing for a planned standalone U.S. commercial launch. 

“We believe this momentum positions us to advance our vision of building the leading rare disease biopharmaceutical company addressing serious, rare skin diseases and vascular malformations with no FDA-approved therapies.”